Immunome, Inc. IMNM R2K
Healthcare · Biotechnology · United States
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
READ MORE ›$21.83
+149.20% 1Y
Market & Price
Market Cap
$2.47B
Current Price
$21.83
High / Low (52W)
$26.97 / $8.40
Beta
2.12
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$5.20
Price to Book
4.20
P/S
615.75
EV/EBITDA
-8.36
Dividend Yield
-
Profitability & Returns
ROCE
-35.12%
ROE
-50.14%
ROA
-29.72%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.48
EPS (TTM)
$-2.39
Balance Sheet & Liquidity
Debt/Equity
0.63
Quick Ratio
21.26
Current Ratio
21.68
Debt
$3.69M
Total Assets
$683.19M
Current Assets
$660.78M
Working Capital
$615.79M
Ownership
Promoter Holding
6.30%
Chg in Prom Hold
-
FII / Inst Holding
108.32%
Chg in FII Hold
-0.03%
Financial Snapshot
Enterprise Value
$1.89B
Total Revenue (TTM)
$4.01M
EBITDA
$-226.35M
Free Cash Flow
$-139.31M
Operating Cash Flow
$-196.50M
Shares Outstanding
113.25M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-158.55%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -158.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMNM Immunome, Inc. R2K | 21.83 | - | $2.47B | - | -35.12% | -50.14% | - | -158.55% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 2.36M | 4.26M | 3.56M | 1.03M | 2.36M | - | - | 2.93M | 4.01M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.56M | 50.49M | 60.14M | 72.86M | 59.33M |
| Operating Income | -2.72M | -2.65M | -2.71M | -2.82M | -3.90M | -5.74M | -7.72M | -11.65M | -8.93M | -8.53M | -4.47M | -5.77M | -4.63M | -132.30M | -40.01M | - | - | -44.64M | -46.48M | -60.14M | -72.86M | -59.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.91M | -45.76M | -59.41M | -72.08M | -58.58M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.74M | -2.68M | -2.71M | -8.38M | -3.90M | -5.24M | -7.72M | -11.65M | -8.92M | -8.53M | -4.27M | -5.56M | -4.34M | -129.49M | -36.12M | - | - | -41.64M | -43.40M | -57.46M | -69.90M | -53.84M |
| Diluted EPS | - | - | - | - | -0.37 | -0.46 | -0.65 | -0.96 | -0.74 | -0.75 | -0.35 | -0.46 | -0.36 | -2.51 | -0.60 | -0.78 | - | -0.52 | -0.50 | -0.65 | - | -0.48 |
| R&D Expense | 2.23M | 2.12M | 1.89M | 1.64M | 1.98M | 3.23M | 4.51M | 8.08M | 5.72M | 5.22M | 3.91M | 5.72M | 3.82M | 15.37M | 29.08M | 37.20M | - | 36.87M | 40.45M | 49.19M | - | 46.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 36.90M | 42.75M | 162.50M | 231.05M |
| Operating Income | -10.35M | -12.26M | - | -36.90M | -28.73M | -153.46M | -224.11M |
| EBITDA | - | - | - | -36.27M | -28.00M | -151.35M | -221.16M |
| Interest Expense | - | - | 10.00K | - | - | - | - |
| Pretax Income | - | - | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -10.44M | -17.84M | - | -36.90M | -106.81M | -292.96M | -212.39M |
| Diluted EPS | - | -5.26 | - | -3.09 | -5.38 | -5.00 | -2.43 |
| R&D Expense | 8.82M | 7.49M | 14.11M | 23.27M | 23.09M | 129.54M | 177.29M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -158.55% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +149.20% |
| 6 Months: | +19.29% |
| 3 Months: | -0.14% |
| 1 Month: | -4.88% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 5.06M | 44.52M | - | 24.05M | 148.54M | 240.24M | 683.19M |
| Current Assets | - | - | - | - | 22.65M | 144.70M | 221.34M | 660.78M |
| Cash & Equivalents | - | 2.54M | 39.77M | - | 20.32M | 98.68M | 143.35M | 653.48M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 0 | 847.00K | - | - | - |
| Total Liabilities | - | 1.80M | 3.18M | - | 7.39M | 28.66M | 59.08M | 48.84M |
| Current Liabilities | - | 1.67M | 3.04M | - | 7.33M | 21.83M | 54.31M | 44.99M |
| Long Term Debt | - | - | 134.00K | - | - | - | - | - |
| Total Debt | - | - | - | - | 291.00K | 1.65M | 4.83M | 3.85M |
| Total Equity | -25.20M | -35.63M | 41.34M | - | 16.65M | 119.88M | 181.16M | 634.34M |
| Shares Outstanding | - | - | - | - | 12.13M | 43.25M | 64.46M | 113.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.60M | -12.13M | - | -28.69M | -7.57M | -110.79M | -190.92M |
| Investing Cash Flow | -233.00K | -586.00K | - | -248.00K | -30.48M | -85.06M | 60.80M |
| Financing Cash Flow | 10.77M | 49.94M | - | 32.00K | 116.41M | 240.53M | 640.36M |
| Capital Expenditure | -233.00K | -586.00K | - | -248.00K | -831.00K | -53.51M | -15.93M |
| Free Cash Flow | -9.83M | -12.72M | - | -28.94M | -8.40M | -164.30M | -206.85M |
| Net Change in Cash | - | - | - | -28.91M | 78.36M | 44.67M | 510.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -204.9% | -1,697.3% | -3,228.8% |
| Net Margin % | - | - | - | - | -761.9% | -3,240.4% | -3,060.0% |
| ROE % | 29.3% | -43.1% | - | -221.6% | -89.1% | -161.7% | -33.5% |
| ROCE % | -304.8% | -29.6% | - | -220.8% | -22.7% | -82.5% | -35.1% |
Shareholding Pattern
Insiders
6.30%
Institutions
108.32%
Public Float
115.61%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.98% | 16.97M | $370.45M |
| 2 | T. Rowe Price Investment Management, Inc. | 14.45% | 16.36M | $357.23M |
| 3 | Blackrock Inc. | 7.21% | 8.17M | $178.32M |
| 4 | Redmile Group, LLC | 4.91% | 5.56M | $121.35M |
| 5 | State Street Corporation | 4.77% | 5.40M | $117.88M |
| 6 | Primecap Management Company | 4.23% | 4.79M | $104.53M |
| 7 | Wellington Management Group, LLP | 4.18% | 4.73M | $103.30M |
| 8 | Vanguard Capital Management LLC | 3.91% | 4.43M | $96.70M |
| 9 | Driehaus Capital Management, LLC | 3.62% | 4.10M | $89.50M |
| 10 | Enavate Sciences Gp, LLC | 3.19% | 3.61M | $78.89M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMNM
No recent headlines available.